• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ENALAPRIL Drug Record

  • Summary
  • Interactions
  • Claims
  • ENALAPRIL chembl:CHEMBL578 Approved

    Alternate Names:

    ENALAPRIL
    VASERETIC
    LEXXEL
    VASOTEC
    C09AA02
    (S)-1-(N-(1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)-L-ALANYL)-L-PROLINE
    EPL753
    ENALAPRILUM
    1-(N-((S)-1-CARBOXY-3-PHENYLPROPYL)-L-ALANYL)-L-PROLINE 1'-ETHYL ESTER
    (S)-1-{(S)-2-[1-((S)-ETHOXYCARBONYL)-3-PHENYL-PROPYLAMINO]-PROPIONYL}-PYRROLIDINE-2-CARBOXYLIC ACID
    ENALADEX®
    ENALAPRILA
    ANALAPRIL
    VASOTEC®
    chembl:CHEMBL578
    chemidplus:75847-73-3
    rxcui:3827
    pubchem.compound:5388962
    drugbank:00584

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Drug Class antihypertensive agents
    Year of Approval 1985
    (3 More Sources)

    Publications:

    Wang et al., 2006, Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system., J. Mol. Cell. Cardiol.
    Wang et al., 2008, [Effect of enalapil on renal interstitial fibrosis in rats with unilateral ureteral obstruction]., Zhong Nan Da Xue Xue Bao Yi Xue Ban
    Gardiner et al., 2005, Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR., J. Pharmacol. Exp. Ther.
    de Cavanagh et al., 2000, Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues., Am. J. Physiol. Regul. Integr. Comp. Physiol.
    Liu L et al., 2006, Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers., J Pharmacol Exp Ther
    Haas M et al., 1998, Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease., Kidney Blood Press Res
    Sasaki M et al., 1996, Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies., J Hypertens
    van Essen GG et al., 1996, Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy., Lancet
    Pérez-Castrillón JL et al., 2003, Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms., Am J Hypertens
    Prasad A et al., 2000, Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition., Circulation
    Liu et al., 2006, Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice., J. Cardiovasc. Pharmacol.
    Andújar-Sánchez et al., 2007, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method., FEBS Lett.
    Natesh et al., 2004, Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme., Biochemistry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Luo JQ et al., 2014, Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment., Pharmacogenomics
    Tarkiainen EK et al., 2015, Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril., Br J Clin Pharmacol
    Silva PS et al., 2013, eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol
    Mukae S et al., 2002, Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough., J Hum Hypertens
    Okuda et al., 2002, Analyses of differential gene expression in genetic hypertensive rats by microarray., Hypertens. Res.
    Esposito et al., 2000, Implication of tissue transglutaminase and desmoplakin in cell adhesion mechanism in human epidermis., Mol. Cell. Biochem.
    Iaccarino G et al., 2006, Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension., Clin Pharmacol Ther
    Ziori et al., The effects of enalapril on p53 expression in left ventricular cardiomyocytes after aortic stenosis., In Vivo
    Shankar et al., 2001, Involvement of nitric oxide in the antiaggregatory effect of enalapril., Methods Find Exp Clin Pharmacol
    Costa et al., 2006, Enalapril reduces the expression of nuclear factor-kappaB and c-Jun N-terminal kinase in the renal cortices of five-sixths-nephrectomized rats., Am. J. Nephrol.
    Niimi et al., 2002, Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors., Jpn. J. Pharmacol.
    Oliveira-Paula GH et al., 2015, Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol
  • ENALAPRIL   DSP

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10839195


    Sources:
    NCI

  • ENALAPRIL   BDKRB2

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22706620 12522467


    Sources:
    PharmGKB

  • ENALAPRIL   ACE

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name enalapril + felodipine,Lexxel
    Novel drug target Established target

    PMIDs:
    9661139 8986921 8538349 12799093 10880412 16424790 17618628 15236580 11752352


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • ENALAPRIL   CES1

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25919042


    Sources:
    PharmGKB

  • ENALAPRIL   AGT

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11928713


    Sources:
    NCI

  • ENALAPRIL   GSR

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10712274


    Sources:
    NCI

  • ENALAPRIL   NR3C2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24059494


    Sources:
    PharmGKB

  • ENALAPRIL   PDE5A

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15452190


    Sources:
    NCI

  • ENALAPRIL   CCN2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18812665


    Sources:
    NCI

  • ENALAPRIL   NOS3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22706620


    Sources:
    PharmGKB

  • ENALAPRIL   DPP4

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16678199


    Sources:
    NCI

  • ENALAPRIL   HSPA4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12047041


    Sources:
    NCI

  • ENALAPRIL   VEGFA

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26002049


    Sources:
    PharmGKB

  • ENALAPRIL   NOS1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11712645


    Sources:
    NCI

  • ENALAPRIL   MAPK8

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16772709


    Sources:
    NCI

  • ENALAPRIL   SLCO1B1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16627748


    Sources:
    PharmGKB

  • ENALAPRIL   ADRB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17178264


    Sources:
    PharmGKB

  • ENALAPRIL   APEX1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ENALAPRIL   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16900775


    Sources:
    NCI

  • ENALAPRIL   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • TEND: ENALAPRIL

    • Version: 01-August-2011

    Alternate Names:
    ENALAPRIL Primary Drug Name

    Drug Info:
    Year of Approval 1985
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: ENALAPRIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: ENALAPRIL

    • Version: 14-September-2017

    Alternate Names:
    C468 NCI drug code

    Drug Info:

    Publications:
    de Cavanagh et al., 2000, Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues., Am. J. Physiol. Regul. Integr. Comp. Physiol.
    Wang et al., 2006, Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system., J. Mol. Cell. Cardiol.
    Niimi et al., 2002, Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors., Jpn. J. Pharmacol.

  • PharmGKB: enalapril

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Iaccarino G et al., 2006, Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension., Clin Pharmacol Ther
    Silva PS et al., 2013, eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol

  • TTD: Enalapril

    • Version: 2020.06.01

    Alternate Names:
    D00SEB TTD Drug ID

    Drug Info:

    Publications:

  • DTC: ENALAPRIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL578 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL578

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21